Literature DB >> 12538719

Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse.

Vedran Katavić1, Ivan Kresimir Lukić, Natasa Kovacić, Danka Grcević, Joseph A Lorenzo, Ana Marusić.   

Abstract

We investigated the bone phenotype of mice with generalized lymphoproliferative disorder (gld) due to a defect in the Fas ligand-mediated apoptotic pathway. C57BL/6-gld mice had greater whole body bone mineral density and greater trabecular bone volume than their wild-type controls. gld mice lost 5-fold less trabecular bone and had less osteoclasts on bone surfaces after ovariectomy-induced bone resorption. They also formed more bone in a model of osteogenic regeneration after bone marrow ablation, had less osteoclasts on bone surfaces and less apoptotic osteoblasts. gld and wild-type mice had similar numbers of osteoclasts in bone marrow cultures, but marrow stromal fibroblasts from gld mice formed more alkaline phosphatase-positive colonies. Bone diaphyseal shafts and bone marrow stromal fibroblasts produced more osteoprotegerin mRNA and protein than wild-type mice. These findings provide evidence that the disturbance of the bone system is a part of generalized lymphoproliferative syndrome and indicates the possible role of osteoprotegerin as a regulatory link between the bone and immune system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538719     DOI: 10.4049/jimmunol.170.3.1540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Modulation of unloading-induced bone loss in mice with altered ERK signaling.

Authors:  Jeyantt S Sankaran; Bing Li; Leah Rae Donahue; Stefan Judex
Journal:  Mamm Genome       Date:  2015-11-06       Impact factor: 2.957

Review 2.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

3.  Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1.

Authors:  I K Lukić; D Grcević; N Kovacić; V Katavić; S Ivcević; I Kalajzić; A Marusić
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

4.  Growth-dependent phenotype in FasL-deficient mandibular/alveolar bone.

Authors:  Eva Svandova; Jeremy Sadoine; Barbora Vesela; Amina Djoudi; Herve Lesot; Anne Poliard; Eva Matalova
Journal:  J Anat       Date:  2019-05-30       Impact factor: 2.610

5.  Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.

Authors:  D Grcević; I K Lukić; N Kovacić; S Ivcević; V Katavić; A Marusić
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 6.  Targeting Fas in osteoresorptive disorders.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Ana Marusic
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

7.  The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis.

Authors:  Natasa Kovacić; Ivan Kresimir Lukić; Danka Grcević; Vedran Katavić; Peter Croucher; Ana Marusić
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 8.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

9.  Fas receptor is required for estrogen deficiency-induced bone loss in mice.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Vladimir Grubisic; Karlo Mihovilovic; Hrvoje Cvija; Peter Ian Croucher; Ana Marusic
Journal:  Lab Invest       Date:  2010-01-18       Impact factor: 5.662

10.  FasL Is Required for Osseous Healing in Extraction Sockets in Mice.

Authors:  Karol Alí Apaza Alccayhuaman; Patrick Heimel; Jung-Seok Lee; Stefan Tangl; Franz J Strauss; Alexandra Stähli; Eva Matalová; Reinhard Gruber
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.